<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>研发客研究院 | wechat-feeds</title><link>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</link><description>独立报告、专业分析、深度解读</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 27 Feb 2021 13:32:46 +0800</pubDate><image><url>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</url><title>研发客研究院 | wechat-feeds</title><link>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>Ribon：利用BEACON+平台开发NAD+利用酶抑制剂 | 前沿</title><link>https://mp.weixin.qq.com/s/mdXLh04ElxY8WhwvbYO-aw</link><description></description><content:encoded><![CDATA[Ribon：利用BEACON+平台开发NAD+利用酶抑制剂 | 前沿]]></content:encoded><pubDate>Sat, 27 Feb 2021 09:44:12 +0800</pubDate></item><item><title>China NMPA Approved Tracker: Jan 2021</title><link>https://mp.weixin.qq.com/s/Ith0q2HtrIeLDJSq7lg0pg</link><description></description><content:encoded><![CDATA[China NMPA Approved Tracker: Jan 2021]]></content:encoded><pubDate>Fri, 26 Feb 2021 09:18:13 +0800</pubDate></item><item><title>China Licensing Deals Tracker: Jan 2021</title><link>https://mp.weixin.qq.com/s/Kds8Mk3jFdE0Ls-_TZ1hVg</link><description></description><content:encoded><![CDATA[China Licensing Deals Tracker: Jan 2021]]></content:encoded><pubDate>Wed, 24 Feb 2021 12:18:59 +0800</pubDate></item><item><title>Turnstone：溶瘤病毒和TIL双重开发平台 | 前沿</title><link>https://mp.weixin.qq.com/s/Sr5ML4vXZYLRaTx8OkckYg</link><description></description><content:encoded><![CDATA[Turnstone：溶瘤病毒和TIL双重开发平台 | 前沿]]></content:encoded><pubDate>Mon, 22 Feb 2021 08:30:33 +0800</pubDate></item><item><title>第四批集采落幕，给创新药企哪些启示｜观点</title><link>https://mp.weixin.qq.com/s/ChKJbdLxF5ApXnLohecHHw</link><description></description><content:encoded><![CDATA[第四批集采落幕，给创新药企哪些启示｜观点]]></content:encoded><pubDate>Tue, 09 Feb 2021 21:09:32 +0800</pubDate></item><item><title>TScan Therapeutics的TCR-T：从患者肿瘤中识别共享抗原靶点 | 前沿</title><link>https://mp.weixin.qq.com/s/Cf7tIr7aQ7nPWOzVDmgqNw</link><description></description><content:encoded><![CDATA[TScan Therapeutics的TCR-T：从患者肿瘤中识别共享抗原靶点 | 前沿]]></content:encoded><pubDate>Mon, 08 Feb 2021 16:52:46 +0800</pubDate></item><item><title>胶质母细胞瘤研发的痛点与希望｜分析</title><link>https://mp.weixin.qq.com/s/75YC3mkY-H89hhVtdwKXeA</link><description></description><content:encoded><![CDATA[胶质母细胞瘤研发的痛点与希望｜分析]]></content:encoded><pubDate>Fri, 05 Feb 2021 11:01:09 +0800</pubDate></item><item><title>免疫检查点的新靶点：TIM-3 | 分析</title><link>https://mp.weixin.qq.com/s/7O24_Ur8-kUn5bR7dn5oBA</link><description></description><content:encoded><![CDATA[免疫检查点的新靶点：TIM-3 | 分析]]></content:encoded><pubDate>Thu, 04 Feb 2021 10:36:02 +0800</pubDate></item><item><title>生物类似药集采已成定局｜观点</title><link>https://mp.weixin.qq.com/s/iCAlNOYGLnuA8tRa7-Opsw</link><description></description><content:encoded><![CDATA[生物类似药集采已成定局｜观点]]></content:encoded><pubDate>Fri, 29 Jan 2021 22:21:31 +0800</pubDate></item><item><title>兆科眼科：抓住中国眼科疾病的黄金赛道 | 分析</title><link>https://mp.weixin.qq.com/s/zzOiUinfXn0tHHBVHwL4rQ</link><description></description><content:encoded><![CDATA[兆科眼科：抓住中国眼科疾病的黄金赛道 | 分析]]></content:encoded><pubDate>Fri, 29 Jan 2021 12:12:57 +0800</pubDate></item></channel></rss>